search
Back to results

Using the Lumen Device for Prediabetes Prevention

Primary Purpose

PreDiabetes, Overweight and Obesity

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Lumen
Sponsored by
Tel-Aviv Sourasky Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PreDiabetes

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

BMI ≥ 27 to ≤ 40 HbA1c ≥ 5.7% to ≤6.4% Fasting glucose ≥ 100 mg/dl to ≤ 125 mg/dl Not treated with diabetes-related medications

Exclusion Criteria:

Medications:

  1. Insulin and medications for glycemic control
  2. Antipsychotics
  3. Diuretics
  4. Anti-retrovirals
  5. Corticosteroids
  6. Oncologic treatment
  7. Thyroid hormones (if endocrinological control is good, can be included).

Conditions:

  1. Previous diagnosis of diabetes
  2. G6PD deficiency
  3. Renal disease
  4. Hepatic disease
  5. Pregnancy
  6. Hematological (anemia)
  7. Suffered heart attack, stroke, or transient ischemic attack in the past 6 months
  8. Uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 105 mm Hg)
  9. Treatment of cancer (excluding surgery alone) within the past 2 years (excluding skin cancer)
  10. Reported chest pain, shortness of breath with minimal activity or at rest, or unexplained dizziness or fainting with physical activity
  11. Chronic lung disease (chronic obstructive pulmonary disease or asthma requiring oxygen therapy)

Personal requirements:

  1. Inability to read and understand English
  2. Inability to use a smartphone
  3. Any issues arise with using the Lumen device and application
  4. Aerobic exercise > 3 times per week
  5. Active participation in diet counseling or active weight loss (> 3 kg in the past one month)
  6. Change of diet or physical activity in the last 3 months

Sites / Locations

  • Institute of Endocrinology, Metabolism and Hypertension

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lumen device usage and diet guidelines

Arm Description

Outcomes

Primary Outcome Measures

Weight change
% weight change
Fat percentage
% change in fat percentage

Secondary Outcome Measures

Blood tests changes - glycemic control
HbA1C (%)
Blood tests changes- lipid panel change
Triglycerides, HDL and LDL cholesterol, total cholesterol) - change in mg/dl
Blood tests changes - glycemic control
Fasting glucose (mg/dl)

Full Information

First Posted
September 16, 2020
Last Updated
September 16, 2020
Sponsor
Tel-Aviv Sourasky Medical Center
Collaborators
Metaflow Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04555421
Brief Title
Using the Lumen Device for Prediabetes Prevention
Official Title
Using the Lumen Device for Prediabetes Prevention
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 2020 (Anticipated)
Primary Completion Date
October 2021 (Anticipated)
Study Completion Date
October 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tel-Aviv Sourasky Medical Center
Collaborators
Metaflow Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
To examine the effect of using Lumen on metabolic parameters and anthropometric variables. This will be done from baseline to the end of a 12 weeks intervention in adults with prediabetes..
Detailed Description
A single arm intervention evaluation for 12 weeks (pre-post analysis) was designed for the study. After initial screening of the subjects, they will be familiarized with Lumen and will learn on how to take a measure. After 2 days of using Lumen device at home for acquaintance and calibration, subjects will arrive to the clinic and several baseline measurements will be taken, including blood samples and anthropometric variables. Then, subjects will use Lumen at home and will take a Lumen measurement each day for a period of 12 weeks. Subjects will take a Lumen measurement each morning at fasted state and will get a nutritional plan according to their result. In addition, subjects will be guided to log in the last time they consumed a meal (how long they fasted for), the duration of their sleep, and if they managed to follow the previous day recommendations. Moreover, the Lumen application will encourage the subjects to take more measurement throughout the day, in particular in response to food intake as well as before and after workouts. Lumen coach will remotely support the subjects via Lumen's mobile phone application and will provide clarifications and guidelines if needed based on the Lumen metric. Finally, subjects will return to the clinic for their final assessment which would include taking blood samples and anthropometric variables again. The study will include 40 subjects the most with a minimal target of 30 subjects. The number of subjects was determined based on power analysis made according to a study evaluating HbA1c levels in prediabetic subjects who received low-carb diet for 12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes, Overweight and Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lumen device usage and diet guidelines
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Lumen
Intervention Description
Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
Primary Outcome Measure Information:
Title
Weight change
Description
% weight change
Time Frame
from baseline to 12 weeks
Title
Fat percentage
Description
% change in fat percentage
Time Frame
from baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Blood tests changes - glycemic control
Description
HbA1C (%)
Time Frame
from baseline to 12 weeks
Title
Blood tests changes- lipid panel change
Description
Triglycerides, HDL and LDL cholesterol, total cholesterol) - change in mg/dl
Time Frame
from baseline to 12 weeks
Title
Blood tests changes - glycemic control
Description
Fasting glucose (mg/dl)
Time Frame
from baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: BMI ≥ 27 to ≤ 40 HbA1c ≥ 5.7% to ≤6.4% Fasting glucose ≥ 100 mg/dl to ≤ 125 mg/dl Not treated with diabetes-related medications Exclusion Criteria: Medications: Insulin and medications for glycemic control Antipsychotics Diuretics Anti-retrovirals Corticosteroids Oncologic treatment Thyroid hormones (if endocrinological control is good, can be included). Conditions: Previous diagnosis of diabetes G6PD deficiency Renal disease Hepatic disease Pregnancy Hematological (anemia) Suffered heart attack, stroke, or transient ischemic attack in the past 6 months Uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 105 mm Hg) Treatment of cancer (excluding surgery alone) within the past 2 years (excluding skin cancer) Reported chest pain, shortness of breath with minimal activity or at rest, or unexplained dizziness or fainting with physical activity Chronic lung disease (chronic obstructive pulmonary disease or asthma requiring oxygen therapy) Personal requirements: Inability to read and understand English Inability to use a smartphone Any issues arise with using the Lumen device and application Aerobic exercise > 3 times per week Active participation in diet counseling or active weight loss (> 3 kg in the past one month) Change of diet or physical activity in the last 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Roy Eldor, MD; PhD
Phone
+972-527360680
Email
roye@tlvmc.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Assaf Buch, PhD
Phone
+972-549931033
Email
asafbu@tlvmc.gov.il
Facility Information:
Facility Name
Institute of Endocrinology, Metabolism and Hypertension
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Using the Lumen Device for Prediabetes Prevention

We'll reach out to this number within 24 hrs